Pfizer vaccine boosters are approved for younger age groups – RT Mundo

The US Food and Drug Administration (FDA) has given the green light to give Pfizer vaccine boosters to children ages 5 to 11, citing data collected from ongoing trials. The agency skipped an advisory board meeting normally held before such decisions, saying the matter had been brought up in earlier discussions.

The FDA announced the expanded booster eligibility on Wednesday, acknowledging that while “Covid-19 tends to be less severe in children than in adults”, the Omicron variant of the virus has led to “more children get sick with the disease and are hospitalized” and created a need for reinforcements among younger Americans.

“The FDA is authorizing the use of a single booster dose of the Pfizer-BioNTech Covid-19 vaccine for children 5 through 11 years of age to provide ongoing protection.” FDA Commissioner Robert Califf said, adding that “Vaccination remains the most effective way to prevent Covid-19 and its serious consequences, and it is safe.”

The health regulator went on to say that the new emergency use authorization was based on its “Analysis of Immune Response Data in a Subset of Children from the Ongoing Randomized Placebo-Controlled Trial,” which indicated that immunity was stronger in those who received a booster. The same trial also served as the basis for the FDA’s decision in October 2021 to approve the initial two-dose vaccines for the 5- to 11-year-old age group.

The FDA restricts the vaccine against covid

While the FDA’s independent Advisory Committee on Vaccines and Related Biologics typically meets to review new authorizations, the agency said that wasn’t necessary because of “extensive discussions on the use of booster doses” in the past. Pfizer Application to Expand Eligibility “did not raise questions that would benefit from further discussion by committee members,” he added.

The Centers for Disease Control and Prevention (CDC) is expected to issue its own recommendation following a meeting scheduled for this week, while Pfizer and pharmaceutical giant Moderna are due to meet with FDA officials next month to discuss the approval to vaccinate children under 5, according to CNBC.

The vaccine co-developed by Pfizer and its partner BioNTech was the first in the US to receive emergency authorization in December 2020, followed by Moderna and Johnson & Johnson. However, the FDA has since scaled back approval of the latter company’s vaccine, limiting it to adults only earlier this month, flagging potentially dangerous side effects for children.

You can share this story on social networks:

Leave a Comment